ArticleActa anaesthesiologica Scandinavica2026
Glucose Management in the ICU: The Bi-Centre GEM-ICU Cohort Study.
Article in Acta anaesthesiologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDysglycaemia is common in intensive care unit (ICU) patients and has been associated with worse outcomes. Data on glucose management and insulin use from contemporary intensive care units (ICUs) are limited.
methodsWe conducted a bi-centre, retrospective cohort study of acutely admitted, adult patients at two Danish ICUs. Patients were included consecutively by backtracking admissions from December 1, 2023, until the target sample size (n = 300) was reached. Data were collected from electronic health records following a predefined protocol. The primary outcome was the occurrence of hypoglycaemia (< 4 mmol/L) during ICU stay. Secondary outcomes included severe hypoglycaemia (< 2.3 mmol/L), hyperglycaemia (> 10 mmol/L), time below blood glucose target range (< 6 mmol/L), time above target range (> 10 mmol/L), mortality at 30 days, days alive without life support at 30 days (DAWOLS) and days alive out of hospital at 30 days (DAOH). Process variables were also assessed.
resultsWe screened 311 ICU patients and included 300, of whom 285 had at least one blood glucose measurement. Hypoglycaemia was observed in 21 patients (7.4%; 95% CI 4.6-11.0) and severe hypoglycaemia in 3 patients (1.1%; 95% CI 0.2-3.0). Hyperglycaemia was observed in 186 patients (65.3%; 95% CI 59.4-70.8). Mortality at 30 days was 24.3% (95% CI 19.6-29.6). Median DAWOLS at 30 days was 27 days (95% CI 26-28; IQR 8-30) and median DAOH at 30 days was 9 days (95% CI 3-14; IQR 0-21).
conclusionIn this Danish bi-centre cohort of acutely admitted ICU patients, hypoglycaemia was uncommon and severe hypoglycaemia was rare, whereas hyperglycaemia occurred in almost every second patient. Insulin was frequently administered, mostly intravenously, and glucose was monitored often. Patients receiving insulin spent nearly half of the observed time above the target range. EDITORIAL COMMENT: In this retrospective analysis from 2 Danish centres, glucose management and insulin use in the ICU is presented. Rare hypoglycemia and more common hyperglycemia measurement events were counted, along with insulin administration, which was common.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.